Clinical Trial Update: MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 [Phase 2]

View source ↗

Summary

Phase 2 trial of MEK inhibitor PD-0325901 in adolescents and adults with Neurofibromatosis Type 1 and growing or symptomatic, inoperable plexiform neurofibromas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• PD-0325901 (PD-0325901)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN | Phase 2 | Status: COMPLETED | Results posted: 2019-01-10